Novo Nordisk A/S
https://www.novonordisk.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Novo Nordisk A/S
Lilly Challenges US FDA Classification Of Obesity Drug Retatrutide, Citing Chevron Overturn
Determining what falls within the statutory definition of ‘biological product’ is an interpretative question that courts, rather than the agency, must resolve, Lilly said in a lawsuit repeatedly citing the US Supreme Court’s June decision in Loper Bright.
Terns’ Early Data May Position It Well In GLP-1 Obesity Race
In a multiple-ascending dose Phase I trial, Terns’ oral GLP-1 agonist showed 4.9% placebo-adjusted weight loss at 28 weeks, with no severe gastrointestinal side effects.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on major topics facing the biopharma sector in the region and more widely.
Obesity Drugs Will Get Broad Commercial Coverage In 2025 Despite Cost Concerns, Survey Says
The Business Group on Health survey also highlights employers’ complicated attitudes on prescription drug rebates in their health benefit programs.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
-
Large Molecule
- Antibodies
- Other Names / Subsidiaries
-
- Carbometrics
- Corvidia Therapeutics
- Neose Technologies, Inc.
- Novo Holdings A/S
- Novo Nordisk Pharmaceuticals, Inc.
- Pharmaero Aps
- Xellia Pharmaceuticals ApS
- Ziylo Ltd
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice